Apr 5, 2012 by Brian Orelli, PhDBad Clinical Trial Trumps Good AcquisitionSpectrum Pharmaceuticals can't get past bad apaziquone data.
Apr 5, 2012 by Brian Orelli, PhDDrug Fails! What's Next for Investors?After getting knocked down, investors ask, "What now?"
Apr 4, 2012 by Brian Orelli, PhDSurprise! Carl Icahn Has Opinion About This Biotech Sale RumorCarl Icahn wants Amylin sold.
Apr 3, 2012 by Brian Orelli, PhDBig Pharma Buys Access to This Promising Biotech PipelineAmgen licenses five drugs to AstraZeneca.
Apr 2, 2012 by Brian Orelli, PhDHigh Risk/High Reward Becomes High FailureBe sure you can take the lumps, biotech investors.
Mar 30, 2012 by Brian Orelli, PhDControversial JOBS Act Will Boost BiotechWeighing investor protection against access to capital.
Mar 30, 2012 by Brian Orelli, PhDDrug Smackdown: Amgen vs. Eli LillyAmgen and Eli Lilly both publish data on their psoriasis drugs.
Mar 30, 2012 by Brian Orelli, PhDKeep an Eye on This PartnershipBristol-Myers and Meso form an Alzheimer's diagnostic partnership.
Mar 30, 2012 by Brian Orelli, PhDThis Cancer Drug Works, but Indication Drama RemainsRoche and ImmunoGen need first-line data.
Mar 30, 2012 by Brian Orelli, PhDAnother Big Setback for Obesity Drug Makers?FDA advisors recommend running trials to measure cardiovascular risk with obesity drugs.
Mar 30, 2012 by Brian Orelli, PhDGattaca, Here We ComeComplete Genomics can process saliva samples now.
Mar 30, 2012 by Brian Orelli, PhDUnlike March Madness, This ACC Is a WinnerHeart companies trump basketball teams.
Mar 29, 2012 by Brian Orelli, PhDWrinkled Bladder? There's a Drug for That!Allergan's Botox works for overactive bladder.
Mar 29, 2012 by Brian Orelli, PhDInvestors Faint From FDA RejectionThe FDA rejects Chelsea's Northera.
Mar 29, 2012 by Brian Orelli, PhDSequence This OfferRoche ups its offer for Illumina; investors want more.
Mar 29, 2012 by Brian Orelli, PhDWill Obesity Drugs Do Better in Europe?Quite possibly, but investors need to temper their enthusiasm.
Mar 29, 2012 by Brian Orelli, PhDBreathe Easy: Program Complete, Data SolidNext up, getting patients to switch.
Mar 29, 2012 by Brian Orelli, PhDBuyout Rumor Has Investors' Blood Sugar PumpingAmylin is playing hard to get.
Mar 29, 2012 by Brian Orelli, PhDHealth Care Reform: Potential Winners and LosersA trinary event in the making.
